Drugs / RD133
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05141253 | Jan 2022 → Nov 2023 overdue | cancer | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05166070 | Jan 2022 → Jan 2024 overdue | cancer | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RD133 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05141253 ↗ |
| Modality | Cell therapy | “Leukapheresis procedure will be performed to manufacture RD133 chimeric antigen receptor (CAR) modified T cells.” NCT05141253 ↗ |
| Route | Intravenous | “RD133 will be intravenously infused at least 24 hours after lymphodepletion preconditioning.” NCT05141253 ↗ |
| Target | MSLN | “the other lentiviral vector expresses MSLN- CAR” NCT05141253 ↗ |